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Abstract 24 
Reproductive ageing is linked to the depletion of ovarian primordial follicles, which causes 25 
an irreversible change to ovarian cellular function and the capacity to reproduce. The current 26 
study aimed to profile the expression of bone morphogenetic protein receptor, (BMPR1B) in 27 
53 IVF patients exhibiting different degrees of primordial follicle depletion. The granulosa 28 
cell receptor density was measured in 403 follicles via flow cytometry. A decline in 29 
BMPR1B density occurred at the time of dominant follicle selection and during the terminal 30 
stage of folliculogenesis in the 23-30 y good ovarian reserve patients. The 40+ y poor 31 
ovarian reserve patients experienced a reversal of this pattern. The results demonstrate an 32 
association between age-induced depletion of the ovarian reserve and BMPR1B receptor 33 
density at the two critical time points of dominant follicle selection and pre-ovulatory follicle 34 
maturation. Dysregulation of BMP receptor signalling may inhibit the normal steroidogenic 35 
differentiation required for maturation in older patients.  36 
  37 
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1. Introduction 38 
Reproductive ageing is linked to the declining capacity to regenerate cells and tissues, 39 
causing irreversible changes to ovarian cellular dynamics and ultimately reducing the 40 
capacity to reproduce. As the average age of fertility-challenged patients climbs towards 40 41 
years (y), there is an urgency to characterise the cellular changes that occur in the ovary with 42 
time. The response of the ovaries to cyclic recruitment of primordial follicles forms the basis 43 
of the clinical documentation of the antral follicle count (AFC) (Almog, et al. 2011). The 44 
AFC and age are highly correlated to histologically determined ovarian primordial reserve 45 
(Hansen, et al. 2011, van Rooij, et al. 2005). As the primordial follicle reserve declines, the 46 
endocrine, paracrine, and autocrine regulation adapts to a changing environment. It is this 47 
changing landscape that requires further investigation to provide an alternative treatment to 48 
preserve the primordial follicles, and to adjust the cellular regulation to achieve oocyte 49 
competence and improve fertility rates in older patients.  50 
 51 
Earlier research has highlighted the potential role of bone morphogenetic protein (BMP) 52 
signalling in regulating ovulation rate in sheep (Campbell, et al. 2006, Galloway, et al. 2000, 53 
Juengel, et al. 2011), and has led us to further investigate the molecular regulation of 54 
folliculogenesis by the BMPs (Regan, et al. 2015, Ruoss, et al. 2009). During a natural cycle, 55 
small antral follicles with sufficient granulosal follicle-stimulating hormone receptor (FSHR) 56 
expression are recruited in response to the intercycle rise in FSH, and one of these is 57 
subsequently selected to become the dominant follicle. Follicles with reduced FSHR and 58 
luteinising hormone receptor (LHR) become less responsive as the dependence from 59 
pituitary FSH stimulation shifts to LH, and circulating FSH concentrations decline (Lapolt, 60 
et al. 1990, Xu, et al. 1995, Zeleznik, et al. 1974). These subordinate follicles are destined 61 
for atresia. The selected dominant follicle is the one with greatest gonadotrophin 62 
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responsiveness, and is dependent on the acquisition of FSHR-induced LHR by granulosa 63 
cells; and this follicle continues growing to the ovulatory stage.  64 
 65 
Previous research has shown that, at the time of declining FSH levels, a reduction in BMP6 66 
(Erickson and Shimasaki 2003), BMP15 (Feary, et al. 2007) and the type 1 TGFβ 67 
superfamily receptor BMPR1B (Feary, et al. 2007, Regan, et al. 2015), occurs after 68 
dominant follicle selection. Once selected, follicle growth and cellular proliferation 69 
continues, leading to an increased oestrogen and inhibin production by the granulosa cells. 70 
Together, these hormones suppress pituitary FSH output further, ensuring the demise of 71 
subordinate follicles. When the threshold for oestrogen’s positive feedback action on the 72 
hypothalamus-pituitary axis is met, preparation for the ovulation phase begins with a 73 
cessation of cell proliferation, and early luteinisation changes taking place. During cellular 74 
and steroidogenic differentiation, activin (Young, et al. 2012), insulin-like peptide 3 (INSL3) 75 
(Anand-Ivell, et al. 2013), anti-mullerian hormone (AMH) (Andersen, et al. 2010, Ogura 76 
Nose, et al. 2012, Weenen, et al. 2004) and gonadotrophin surge attenuating factor (GnSAF) 77 
activity (Martinez, et al. 2002) declines, from dominant follicle selection to the termination 78 
of folliculogenesis at ovulation.  79 
 80 
The functional role of BMPR1B receptor in follicle development has received considerable 81 
attention in recent years following the discovery that hyper-prolific sheep with the Booroola 82 
(FecB) phenotype have a naturally occurring mutation in the kinase domain of BMPR1B that 83 
perturbs antral follicle development and ovulation rate (Souza et al 2001; Mulsant et al 84 
2001). The BMP ligands, 2, 4, 6, 7, and 15 form a receptor-ligand complex with the type 1 85 
TGFβ receptor BMPR1B, and recruit the type 2 TGFβ receptor BMPR2. The complex 86 
initiates phosphorylation of the intracellular substrate molecules, which are the receptor-87 
regulated Smads. The Smad forms a complex with a common mediator, Smad 4, and 88 
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translocates to the nucleus where transcription of BMP-responsive genes takes place. Smad 89 
signalling is modulated by repressor and activator molecules in the nucleus, cytoplasm, and 90 
in the extracellular matrix. Alternatively, BMPs activate the non-Smad pathway mitogen-91 
activated protein kinase (MAPK) such as extracellular signal-regulated kinase (ERK 1/2) or 92 
Ark (Inagaki, et al. 2009, Ryan, et al. 2008) 93 
 94 
In the ovary, granulosa cell signalling induced by the gonadotrophins, FSH and LH, activate 95 
the FSHR or LHR and stimulate cAMP-PKA, which increases the CYP19A1 aromatase to 96 
facilitate oestrogen synthesis. Progesterone synthesis is inhibited by the suppression of 97 
steroidogenic regulatory protein (StAR) (Abdo, et al. 2008, Pierre, et al. 2004, Tajima, et al. 98 
2003, Val, et al. 2003), which is essential for progesterone synthesis in the granulosa cell 99 
(Moore, et al. 2001). Alternatively, or in addition, BMPs inhibit ERK 1/2 signalling, which 100 
provides inhibitory control over the balance of progesterone and oestrogen (Miyoshi, et al. 101 
2007, Nakamura, et al. 2012, Ogura Nose, et al. 2012).  102 
 103 
Given the particular focus of interest on BMPR1B in ovarian function, the current study 104 
aimed to comprehensively profile the expression of granulosal BMPR1B in a range of 105 
patients, of different ages and stages of ovarian primordial follicle depletion, who were 106 
receiving treatment for infertility. Previous reports documenting ovarian BMPR1B 107 
expression have evaluated expression at the mRNA level in pooled follicles from different 108 
size classes (Chen, et al. 2009, Estienne, et al. 2015). However, mRNA expression does not 109 
necessarily reflect expression of translated functional BMPR1B protein on the cell surface. 110 
In contrast, in this study we collected an average of ~ 8000 granulosa cells from each 111 
individual follicle over a comprehensive range of follicle diameters from 4 mm to 27 mm. 112 
Immunofluorescent labelling and flow cytometry were then used to measure the granulosa 113 
cell surface-expressed mature receptor protein density for the BMPR1B receptor. 114 
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2. Materials and Methods  115 
2.1. Patients 116 
A total of 401 follicles were collected from 53 patients undergoing standard fertility 117 
treatment previously reported in accordance with the PIVET Medical Centre Algorithm, and 118 
are presented in Table 1  (Yovich, et al. 2012). Follicles were collected irrespective of 119 
previous aetiology, but limited to exclude unusual medical conditions, hormonal 120 
dysfunction, and polycystic ovarian syndrome; patients were aged between 23 and 45 y. One 121 
patient, out of three patients undergoing risk reduction removal of the uterus and ovaries, 122 
was selected to represent an unstimulated natural healthy cycle prior to the LH surge, and 123 
was recruited from King Edward Memorial Hospital (KEMH).  124 
Table 1 Patient ovarian reserve, based on antral follicle count (AFC) and the number of 125 
follicles collected per group. 126 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number 127 
of follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 128 
13-19; C = 9-12, D = 5-8; E = ≤4.  129 
 130 
 131 
2.2. Human IVF: Ovarian stimulation, follicular fluid and oocyte 132 
Patient treatment consisted of two types of GnRH-LH suppression in conjunction with rFSH, 133 
from cycle day 2 for ~ 10 days (Puregon or Gonal F). A GnRH antagonist treatment 134 
(Cetrotide) (0.25 μg/day) was administered from day seven until ovulation induction. 135 
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  B 50 C 16 D 30 E            6
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
OVARIAN  
RESERVE 
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Alternatively, a GnRH flare agonist treatment (Lucrin) (0.25 μg/day) was administered in 136 
conjunction with rFSH on day 2, Ovulation was triggered with either 10 000 IU hCG derived 137 
from a urinary preparation (Pregnyl) or a pituitary derived analogue to LH (Ovidrel). Oocyte 138 
retrieval was scheduled for 36 hours post-trigger, by transvaginal oocyte aspiration (Yovich 139 
and Stanger 2010). 140 
2.3. Antral follicle count  141 
Patients received rFSH based on the patient’s profile of age and AFC, to predict the rFSH 142 
dose required to stimulate multiple pre-ovulatory follicles (Yovich, et al. 2012). The dose of 143 
rFSH was then adjusted to the patient’s ovarian response to stimulation. Considerable 144 
overlap in rFSH dose was present between age groups, which allowed for a rFSH dose 145 
comparison between different ovarian reserve patient groups of the same age. Ovarian 146 
reserve was measured indirectly by the antral follicle count (AFC) (Hansen, et al. 2011). 147 
AFC was defined as the number of follicles between 2-10 mm in size that are present on day 148 
2-5 of a cycle. Determination of AFC was ascertained by transvaginal ultrasound and 149 
patients were divided into groups accordingly: Group A+ = 30-39; group A = 20-29; group B 150 
= 13-19; group C = 9-12, group D = 5-8; group E = ≤ 4. The groups were established based 151 
on ovarian response to gonadotrophin hormone stimulation during IVF cycles. (Yovich, et 152 
al. 2012).  153 
2.4. Collection of granulosa cells 154 
The diameter of the follicle was calculated using ultrasonography before the clinical 155 
aspiration of individual follicles. The first aspiration was collected without flush medium 156 
into a test tube, and handed to the embryologist to locate the oocyte and attached cumulus 157 
cells if present. Further flushing of the follicle (Quinn’s Advantage with Hepes, Sage Media, 158 
Pasadena, California) at ~ 1.24-1.72 MPa removed the loosely attached layers of granulosa 159 
cells. Once the oocyte was located and removed, the clinician proceeded to the next follicle 160 
and repeated the process. The follicular fluid and flush was then layered onto a ficoll density 161 
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gradient (555485; BD Biosciences, Perth, Australia) and centrifuged to isolate the granulosa 162 
cells  163 
2.5. Natural healthy unstimulated cycle collection  164 
The natural cycle patients scheduled for risk reduction removal of the reproductive organs 165 
was timed to coincide with day 12 of the menstrual cycle (Table 1). Before removal, 166 
ultrasound confirmation of the size of the follicles and the number of follicles present was 167 
made. After removal of the uterus and ovaries, the whole follicle was excised and 168 
transported to the laboratory. The collection of follicular fluid, isolation of the granulosa 169 
cells, and the analysis was performed as described above and below. 170 
2.6. Immunolabelling of granulosa cells 171 
Aliquots of suspended granulosa cells (1x10⁶ cells in 100 µl) were immunolabelled using a 172 
double-indirect method as previously described (Abir, et al. 2008, Cai, et al. 2007, Gao, et al. 173 
2007). The cells were incubated separately with an optimised concentration of 4 μg/ml 174 
affinity purified polyclonal antibody to goat BMPR1B (sc-5679), (Santa Cruz 175 
Biotechnology, Santa Cruz, CA, USA), for 25 min at 5˚C; washed with PBS and then 176 
incubated with a second antibody, donkey anti-goat conjugated to the flurochrome Alexa 177 
488 (Al-Samerria and Almahbobi 2014 ). The cells were washed again with PBS and 178 
centrifuged at 300 g at 5˚C for 5 min. In addition, these antibodies have been used previously 179 
in human studies (Abir, et al. 2008, Haÿ, et al. 2004), including flow cytometry analyses 180 
(Gao, et al. 2007, Regan, et al. 2015, Whiteman, et al. 1991). 181 
 182 
The routinely used monoclonal antibody against CD45 was added to BMPR1B antibody-183 
containing tubes to enable the subtraction of leukocyte common antigen-positive cells (~ 184 
3%) not removed during isolation of the granulosa cells using the ficoll density gradient. 185 
Unstained samples or the substitution of primary antibody with pre-immune goat IgG (Fig. 186 
1A) (Millennium Science, Surrey Hills, Victoria Australia) at the same concentration of the 187 
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primary antibody served as a negative control for auto-fluorescence; and a blocking peptide 188 
for BMPR1B also confirmed binding specificity (Fig 1B), (sc-5679P; Millennium Science, 189 
Surrey Hills, Victoria Australia) and as previously published (Abir, et al. 2008, Al-Samerria 190 
and Almahbobi 2014 , Haÿ, et al. 2004, Regan, et al. 2015, Weall, et al. 2014)  191 
In the current study, the ‘normal’ goat IgG and unstained control cells emitted an average 192 
MFI that was very similar for each individual follicle but different between follicles and 193 
patients; therefore, to optimise accuracy, the auto-fluorescence and the nonspecific binding 194 
determined by the unstained control for each follicle, was subtracted from each individual 195 
follicle. The data were analysed using FlowJo software (Tree Star Inc., Oregon, USA). 196 
Fig. 1 Validation of immunofluorescent labelling.  197 
A. Unstained control (blue) compared to IgG Isotope control (red) for nonspecific binding 198 
and auto-fluorescence. B. Live human granulosa luteal cells with positive fluorescence for 199 
BMPR1B (EF), and negative blocking agent for BMPR1B (GH). Bar 10 µm. 200 
 201 
2.7. Fluorescent microscopy 202 
Re-suspended 10µl aliquots of BMPR1B immunolabelled, live granulosa cells were placed 203 
on slides and visualized using an Olympus DP 70 camera fitted to a Olympus BX-51 upright 204 
fluorescent microscope with a 40x UPlan N 0.4 N.A. objective; (Olympus Imaging 205 
Australia, Macquarie Park, Australia), (Fig.1B). The granulosa cell slides were allowed to air 206 
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dry to reduce movement during digital capture, which would account for the more clumpy 207 
appearance compared to the more typical single granulosa cells analysed by flow cytometry. 208 
Fluorescent microscopy revealed a positive staining of the cell membrane-bound BMPR1B, 209 
as an intermittent, bright, ring-like pattern around the cells. All control samples showed 210 
negative staining. Granulosa cells ranged from 8 µm to 25 µm, with the average being 15 211 
µm. 212 
2.8. Flow cytometry  213 
Selective gating of the whole sample to identify a pure granulosa cell population was 214 
achieved by graphing forward scatter to remove doublets (FSC-H verses FSC-A) (Regan, et 215 
al. 2015). Then Alexa Fluor 488 fluorescent intensity was plotted against Allophycocyanin 216 
(APC) intensity to identify and subtract the cells positive for the leukocyte common antigen 217 
antibody CD45, which emits in the APC spectrum (Fig. 2A). Auto-fluorescence and 218 
nonspecific binding were identified by the unstained sample control BMPR1B expression, 219 
and subtracted from the measurement (Fig. 2B).  220 
Fig. 2 Validation of gating to measure average receptor density in flow cytometry. 221 
 222 
A. Unstained control granulosa cells, represented as blue dots (auto-fluorescence) and 223 
immunostained granulosa cells (grey). A rectangle subtraction gate for the leukocyte 224 
common antigen CD45 positive cells. B. Subtraction of nonspecific binding and auto-225 
fluorescence at 10³; mean granulosa cell fluorescent intensity (MFI) measurement.  226 
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2.9. Statistics 228 
Mean fluorescent intensity (MFI) was obtained using ~8000 granulosa cells per individual 229 
follicle for the direct measurement of receptor protein expression. The data were subjected to 230 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 231 
follicular size using GraphPad Prism 6. Values in graphs are means ± S.E.M., and 232 
differences were considered significant if *p<0.05, **p<0.01, ***p<0.005, and 233 
****p<0.001. The letter, such as ‘a’, signifies a statistical difference to the matching letter, 234 
and an attached asterisk (a*) indicates the significance level for that follicle size category.  235 
2.10. Human Ethics 236 
Informed consent was obtained from 57 patients undergoing standard fertility treatment at 237 
PIVET fertility clinic Perth, Australia, and three patients undergoing risk reduction removal 238 
of the uterus and ovaries which were recruited from King Edward Memorial Hospital 239 
(KEMH) Perth, Australia. Approval by the Human Research Ethics Committee of Curtin 240 
University of Technology and KEMH Women and Newborn Health Service ethics 241 
committee (WNHS) was obtained for this study. 242 
3. Results 243 
3.1. Follicle development and ovarian reserve 244 
Relative to older (40+y) patients, the level of granulosal BMPR1B expression was lower in 245 
the 23-30 y IVF patients in combined AFC groups A+ & A, and showed a biphasic receptor 246 
density pattern (Fig. 3). The biphasic pattern of receptor density consisted of an initial 247 
decrease in BMPR1B in follicles from 8 mm to 10 mm (p<0.0201), followed by an up-248 
regulation in the follicles to 16 mm (p<0.0084), which was further followed by a significant 249 
decline in follicles to the terminal-end of folliculogenesis of 24-26 mm (p<0.0301, Fig. 3). In 250 
marked contrast, the BMPR1B density increased with follicular size (p<0.0044) in a 251 
monophasic reversed profile in the 40+ y group (Fig. 3). The level of receptor density in the 252 
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small antral follicles of 8 mm was greater in the young patients than the older patients 253 
(p<0.0405). 254 
In a natural healthy cycle, the granulosa cells were collected from a healthy 40+ y with a 255 
group D AFC. When combined, the two follicles of 10 mm and 18.5 mm had a significantly 256 
lower density of BMPR1B compared to the largest follicles of the 40+ y IVF patients with a 257 
group D & E AFC (Fig. 3). The receptor level in the natural cycle was not significantly 258 
different to the level recored in the younger patients and provides a baseline comparison. 259 
with the limitation of reduced interpretation.  260 
 261 
Fig. 3 Granulosal BMPR1B density from follicles of different sizes collected from young 262 
and older IVF patients compared to an unstimulated natural healthy cycle. 263 
 264 
Granulosal BMPR1B protein density and follicle size profile of a natural healthy 265 
unstimulated patient of 41y with an AFC of D, before the LH surge (patterned bar). Patients, 266 
23-30 y stimulated, IVF cycle with an AFC of A+ & A, (grey bar). Patients, 40+ y 267 
OVARIAN  
RESERVE 
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stimulated IVF cycle with an AFC of D & E, (white bar). IVF patients were grouped 268 
according to ovarian reserve measured indirectly by the antral follicle count (AFC). Mean 269 
fluorescent intensity (MFI) was obtained using an average of ~ 8000 granulosa cells per 270 
follicle for the direct measurement of receptor protein expression. The data were subjected to 271 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values in 272 
graphs are means ± S.E.M., and differences were considered significant if *p<0.05 and 273 
**p<0.01. The letter, ‘a’ signifies a statistical difference to the matching letter with an 274 
attached asterisk(s) (a*, a**). The number within the column represents the number of 275 
follicles analysed for that group. 276 
  277 
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3.2. Dysregulation of BMPR1B receptor density young patients with poor ovarian 278 
reserve 279 
In the youngest age group 23-30 y, the majority of the patients had an AFC within groups 280 
A+ & A (Fig. 4). There was no significant difference between the A+ group and the A group. 281 
In contrast, the follicles from the C group patients with low AFC had increased BMPR1B 282 
expression compared to the similar size follicles in the A+ & A group (p<0.05 to p<0.001, 283 
Fig. 4), similar to the profile of the 40+y E AFC patients. Young patients with a very poor 284 
ovarian reserve (group C) for their age do not typically have many follicles available for 285 
collection. The rFSH dose administered ranged from 87 IU to 150 IU in the A+ & A group, 286 
and was 190 IU in the C group. 287 
Fig. 4 Granulosal BMPR1B density and ovarian reserve depletion in 23-30 year-old patients. 288 
 289 
Patients were grouped according to ovarian reserve measured indirectly by the antral follicle 290 
count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. The 291 
data were subjected to statistical verification using one-way ANOVA with an uncorrected 292 
OVARIAN  
RESERVE 
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Fisher’s LSD. Values are means ± S.E.M., and differences were considered significant if 293 
*p<0.05. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and an 294 
attached asterisk (a*) which indicates the significance level. The number within the column 295 
represents the number of follicles analysed for that group. 296 
 297 
3.3. Association between AFC and BMPR1B receptor density in older (31-34y) 298 
patients  299 
In the 31-34 y age group, the decline in ovarian reserve was associated with a loss of 300 
receptor density of BMPR1B in the granulosa cells from a peak in the 19 mm follicles in the 301 
A group to a significantly lower value in the B and C groups (p<0.002, Fig. 5A). The rFSH 302 
dose given ranged from 83.5-266 IU, and when the AFC group comparison was restricted to 303 
those patients who received a comparable rFSH dose (200-233 IU), a similar BMPR1B 304 
receptor density profile was observed in the B and C group patients. However, in group A, 305 
the profile was different in the 16-19 mm follicles, which showed reduced receptor density 306 
(Fig. 5B). 307 
308 
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Fig. 5 Granulosal BMPR1B density and ovarian reserve depletion in 31-34 year-old patients. 309 
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 310 
A. Patients were grouped according to ovarian reserve measured indirectly by the antral 311 
follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. 312 
B. As above, patients were grouped according to AFC but only those who received an 313 
equivalent rFSH dose were included in the analysis. Data were subjected to statistical 314 
verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values are means ± 315 
S.E.M., and differences were considered significant if *p<0.05. The letter, such as ‘a’ 316 
signifies a statistical difference to the matching letter with an attached asterisk (a*) which 317 
indicates the significance level (ie. ‘a’ is s.d. to all a*). The number within the column 318 
represents the number of follicles analysed for that group.  319 
 320 
3.5. BMPR1B receptor density in older patients with declining AFC 321 
The 35-39 y combined B & C group demonstrated a significant reduction in BMPR1B 322 
receptor density in the 10 mm to 16 mm follicles (p=0.007), similar to the youngest age 323 
group. With a further decline of the ovarian reserve (group D & E) the receptor density in the 324 
smaller follicles was reduced followed by a steady increase with increasing follicular size 325 
similar to the oldest patients monophasic profile, (p=0.037), Fig. 6A). The rFSH dose given 326 
ranged from 83.5-600 IU, and when the AFC group comparison was restricted to those 327 
patients who received a similar FSH dose (190-241 IU), a very similar BMPR1B receptor 328 
density profile was observed (Fig. 6B).  329 
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Fig. 6 Granulosal BMPR1B density and ovarian reserve depletion in 35-39 year-old patients. 330 
 331 
A. Patients were grouped according to ovarian reserve measured indirectly by the antral 332 
follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. 333 
B. As above, patients were grouped according to AFC but only those who received s similar 334 
rFSH dose (190-241 IU) were included in the analysis. Data were subjected to statistical 335 
verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values are means ± 336 
OVARIAN  
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S.E.M., and differences were considered significant if *p<0.05. The number within the 337 
column represents the number of follicles analysed for that group.  338 
The 40+ y patients (40-45 year-old) ranged in AFC from group B to group E (Fig. 7A). The 339 
group B & C patients combined demonstrate a higher BMPR1B receptor density in the small 340 
follicles, followed by significant down-regulation of receptors as follicle size increased 341 
(p<0.0176). With a decline in the ovarian reserve to group D, the receptor density in the 342 
smaller follicles was reduced compared to group B (p<0.0059). With a further decline of 343 
ovarian reserve from D to group E, the receptor density significantly increased (19 mm 344 
follicles, p<0.03); and within the E group increased with follicle size (10 mm to 22 mm, 345 
p<0.0058, Fig. 7A). This was similar to the ageing effect observed in the youngest group C 346 
patients (Fig 4). The rFSH dose given ranged from 300-600 IU, and when the AFC group 347 
comparison was restricted to those patients who received an identical FSH dose (600 IU), a 348 
very similar BMPR1B receptor density profile was observed (Fig. 7B). 349 
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Fig. 7 Granulosal BMPR1B density and ovarian reserve depletion in 40+ year-old patients. 350 
  351 
A. Patients were grouped according to ovarian reserve measured indirectly by the antral 352 
follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. 353 
B. As above, patients were grouped according to AFC but only those who received an 354 
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equivalent rFSH dose (600IU) were included in the analysis. Data were subjected to 355 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values are 356 
means ± S.E.M., and differences were considered significant if *p<0.05 and **p<0.01. The 357 
letter, such as ‘a’ signifies a statistical difference to the matching letter, and an attached 358 
asterisk (a*) which indicates the significance level (ie. ‘a’ is s.d. to all a*). The number 359 
within the column represents the number of follicles analysed for that group.  360 
 361 
4. Discussion 362 
A continuous process of activation of primordial follicles in the ovary leads to the inevitable 363 
depletion of the ovarian reserve in women (Almog, et al. 2011). The gradual decline in 364 
ovarian reserve can be indirectly measured by the number of small antral follicles at the 365 
beginning of a cycle, which is termed the AFC (Hansen, et al. 2011). The response of the 366 
ovary to exogenous gonadotrophins used to treat infertility declines with age, which is 367 
strongly correlated to the ovarian reserve (Hansen, et al. 2011). Patients with a poor ovarian 368 
reserve are treated with increasing doses of rFSH in an attempt to increase the number of 369 
small antral follicles with sufficient FSHR to develop into pre-ovulatory follicles.  370 
 371 
In sheep carrying the Booroola (FecB) mutation, follicle development was perturbed and 372 
ovulation rate increased as a consequence of a point mutation in the BMPR1B gene (Regan, 373 
et al. 2015). Therefore, the potential role of BMPR1B within the context of follicle 374 
development, ovarian ageing, and fertility in humans is of considerable interest. In the 375 
present study, the density of expression of mature cell surface protein for BMPR1B was 376 
measured by flow cytometric analysis. We found that a reduction in the number of growing 377 
follicles was linked to the sequential disruption of BMPR1B density on the surface of 378 
granulosa cells.  379 
 380 
Ovarian reserve depletes sequentially with age in a slow continuous process.  The results in 381 
this study show a gradual degradation in the density of receptors, which is perpetuated 382 
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through the different age groups. The change observed may appear difficult to interpret; 383 
however, within each age group, there is evidence of over-expression followed by a 384 
weakness in expression, a lack of down-regulation, and eventually, reduced receptor density, 385 
ultimately leading to increased levels of BMPR1B in the largest follicles of the oldest, 386 
poorest ovarian patient groups. 387 
 388 
An important finding of this study was that a decline in granulosal BMPR1B receptor 389 
density occurs in follicles of a size that would correspond to the time of cyclic dominant 390 
follicle selection, and again in the largest follicles from the best prognosis IVF patients, aged 391 
23-30 y. In comparison, the older, 40+ y, poor ovarian reserve patients exhibited a reversal 392 
of this pattern (Fig. 3). The emergence of the dominant follicle in a natural cycle and the 393 
multiple ‘dominant’ follicle cohort of an IVF stimulated cycle occur at the same follicular 394 
size (Baerwald, et al. 2003, Baerwald, et al. 2009). The growth rate of ovulatory follicles 395 
from a major wave was also not significantly different in an IVF cycle  (Baerwald, et al. 396 
2009). The rFSH only extends the window of recruitment that promotes multiple dominant 397 
follicles (Baird 1987, Fauser and Van Heusden 1997). Therefore, it is possible to compare 398 
the receptor density to the physiological process indicated by the size of the follicle, such as 399 
dominant follicle selection. It is, therefore, speculated that enhanced BMP signalling arising 400 
from elevated pre-ovulatory BMPR1B levels would inhibit the normal steroidogenic 401 
differentiation required for maturation of the follicle in older patients with reduced AFC. A 402 
decrease in small antral follicle number has been associated with a rise in luteal and start-of-403 
cycle FSH and LH with a corresponding decrease in inhibin B, AMH, and IGF 1(Klein, et al. 404 
2000, Pal, et al. 2010). The increase in FSH and LH has been shown to accelerate the early 405 
growth of small follicles, followed by reduced growth rates of the pre-ovulatory follicles in 406 
older patients. Other ovarian age related changes were associated with an increase in 407 
mitochondrial deletions in granulosa cells (Seifer, et al. 2002) and an increase in the number 408 
of chromosomal errors (Handyside, et al. 2012).  409 
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4.1. BMPR1B down-regulation and dominant follicle selection 410 
The biphasic down-regulation of the density of the TGFβ superfamily type I receptor, 411 
BMPR1B, during folliculogenesis was similar to our previous finding in unstimulated young 412 
adult sheep (Regan, et al. 2015). During dominant follicle selection in sheep, and at an 413 
equivalent size in gonadotrophin stimulated humans, granulosal expression of BMPR1B was 414 
reduced, followed by a sequential increase with follicle size (Fig 3). The similarity between 415 
the sheep in natural cycles and the human IVF model suggests that rFSH has minimal impact 416 
on receptor expression levels and on the timing of dominant follicle selection. The addition 417 
of gonadotrophin in the form of rFSH masks the normal physiological pituitary drop in FSH, 418 
allowing a prolonged recruitment phase that enables multiple follicles to grow (Rice, et al. 419 
2007). The process of recruitment and dominant follicle selection should therefore be 420 
comparable to a normal unstimulated IVF cycle. 421 
 422 
In other studies, granulosa cell expression of BMPR1B has been shown to increase with 423 
follicle size (Chen, et al. 2009, Estienne, et al. 2015), which is consistent with our findings. 424 
However, the pre-ovulatory, leading dominant follicle in sheep was pooled with smaller 425 
follicles in these studies, which would effectively mask the down-regulation (Regan, et al. 426 
2015). The down-regulation of granulosa cell BMPR1B expression in the present study was 427 
consistent with findings for sheep dominant follicles compared to the subordinate follicles 428 
reported in another recent study (Gasperin, et al. 2014). The interrelationship between FSH 429 
and BMP regulation has been previously reported (Miyoshi, et al. 2006, Shi, et al. 2009, Shi, 430 
et al. 2010), and the decline in pituitary FSH secretion initiating the dominant follicle 431 
selection process would, therefore, appear to be temporally related to the decline in 432 
BMPR1B expression on the granulosa cell surface. The low levels of receptor expression in 433 
the small antral follicles of older patients with reduced ovarian reserve suggest a possible 434 
cause of poor quality follicles and oocytes typical of older patients. Oocytes surrounded by 435 
cumulus cells with greater levels of BMP15 mRNA were shown to have an increased 436 
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pregnancy rate after IVF (Li, et al. 2014), and reduced apoptosis (Hussein, et al. 2005). 437 
Moreover, an association between high levels of BMP15 in the follicular fluid and oocyte 438 
quality has been reported (Li, et al. 2014, Wu, et al. 2007). 439 
4.2. BMPR1B down-regulation and the maturation of pre-ovulatory follicles  440 
The degenerative ageing of granulosal BMPR1B density is highlighted by the observation 441 
that 40+ y patients (groups B & C) with a favourable ovarian reserve for age exhibit a 442 
pattern of declining receptor density with follicle size, whereas the pattern in the 40+ y 443 
patients (groups D & E) with reduced ovarian reserve is reversed (Fig. 7). Similar ovarian 444 
ageing was found in the 35-39 y B & C group with the same steady increasing density in the 445 
reduced ovarian reserve D & E group (Fig. 6). In addition, evidence of ovarian ageing was 446 
seen in the youngest patients with a severely reduced for age ovarian reserve (AFC group C), 447 
where the receptor density was increased substantially (Fig. 4). The over-expression of 448 
BMPR1B was also present in the oldest patients with severe ovarian depletion (AFC E; Fig 449 
7A). In the 31-34 y patient group with an A ovarian reserve, the receptor density increased in 450 
the largest follicles followed by a general decrease in the poorer ovarian reserve patients for 451 
that age group (Fig. 5A). As age increases, and the ovarian reserve declines, fewer follicles 452 
are stimulated; hence, the extra-large follicles are rare. In the younger patients of 31-34 y, it 453 
would be expected that a 24+ mm follicle would be common; however, none were analysed.  454 
The reversal of receptor density provides evidence of a fundamental shift in granulosal 455 
BMPR1B receptor density with ovarian ageing. High levels of BMPR1B in pre-ovulatory 456 
follicles would promote oestrogen synthesis and inhibit progesterone synthesis, which could 457 
potentially supress maturation of the follicle (Otsuka 2010, Shimasaki, et al. 1999).  458 
4.3. Could the apparent effect of ovarian ageing on BMPR1B receptor density be due 459 
to different degrees of rFSH stimulation in the treatment cycle?  460 
Patients with declining ovarian reserves are prescribed greater doses of rFSH and this could 461 
potentially confound the interpretation of the present observation that ovarian ageing affects 462 
granulosal BMPR1B receptor density. However, when ‘like-with-like’ comparisons were 463 
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made, with only those patients prescribed similar doses of rFSH included in the analyses, the 464 
effect of ovarian ageing on receptor expression persisted. The changes observed in BMPR1B 465 
density are therefore, unlikely to be attributable to the degree of rFSH stimulation that the 466 
patient received during a treatment cycle, at least within patients of a similar chronological 467 
age. In support of this, unpublished findings from one of our laboratories (PGK) have 468 
indicated that treatment of cultured bovine granulosa cells with FSH promotes a marked 469 
increase in CYP19A1 mRNA expression and E2 secretion but has no effect on BMPR1A, 470 
BMPR1B or BMPR2 mRNA expression (C Glister and PG Knight, unpublished 471 
observations).  472 
4.4. Ovarian gonadotrophin surge attenuating factor (GnSAF) and BMPR1B 473 
receptor density during folliculogenesis: is there a link? 474 
 The BMPs have been described as inhibitors of the LH surge and luteinisation (Otsuka 475 
2010, Shimasaki, et al. 1999). GnSAF is an uncharacterised follicular-derived factor 476 
purported to reduce GnRH-induced pituitary LH secretion (Dimitraki, et al. 2014). An 477 
inverse relationship between GnSAF activity and follicle size has been reported (Fowler, et 478 
al. 2001). Furthermore, the age-related decline in ovarian reserve was associated with 479 
reduced GnSAF activity during follicle development (Martinez, et al. 2002). Could this be 480 
linked to the somewhat similar effect of age on granulosal BMPR1B receptor density shown 481 
in the present study? In the current study the observed changes in granulosal BMPR1B 482 
density in the young and older patients mimic the changes in GnSAF activity described by 483 
Martinez et al. (2002). Martinez et al. (2002) concluded that the GnSAF bioactivity 484 
prevented the premature onset of the LH surge, which bears comparison with the proposed 485 
role of BMPs as an inhibitor of luteinisation as evidenced by others (Otsuka 2010, 486 
Shimasaki, et al. 1999). In this context, it should be mentioned that both BMP ligands and 487 
receptors are expressed at the anterior pituitary gland level and BMP signalling has been 488 
implicated in the regulation of gonadotrophin production (Nicol et al 2008). Thus, it is 489 
tempting to speculate that ovarian GnSAF bioactivity, as yet uncharacterised, might actually 490 
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be attributed to BMPs synthesized and secreted by ovarian follicles. Clearly, further detailed 491 
experiments would be required to evaluate the tenability of this suggestion. 492 
4.5. Conclusion 493 
Taken together, the results demonstrate the disrupting effect that ageing-induced depletion of 494 
the ovarian reserve has on granulosal BMPR1B receptor density in antral follicles. Age-495 
induced depletion is associated with a loss of the biphasic down-regulation of granulosal 496 
BMPR1B density during follicle development.  The findings extend previous research by the 497 
comprehensive nature of the range of follicle sizes and age groups studied, together with 498 
measurement of the translated mature, BMPR1B protein as opposed to measurement of 499 
receptor expression at the mRNA level (Ascoli, et al. 2002). Further work is needed to 500 
confirm the identity of the locally-produced TGFβ family ligand(s) (BMP2, BMP4, BMP6, 501 
BMP 7, and BMP15) whose signalling may either promote, or be impacted by this change in 502 
BMPR1B receptor density on the granulosa cell surface, and also to explore the 503 
consequences of altered signalling.  504 
  505 
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